Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab

Files
dewet_pyoderma_2017.pdf(1.39 MB)
Date
2017
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
University of California
Abstract
PASH syndrome (pyoderma gangrenosum, acne, and suppurative hidradenitis) forms part of the spectrum of autoinflammatory diseases. We report an unusual case of PASH syndrome in a patient with end-stagerenal disease (ESRD) who was successfully treated with the tumor necrosis factor inhibitor, adalimumab. The case underscores the challenges associatedwith the treatment of PASH syndrome as well as the ongoing search to establish a genetic basis for the syndrome. Renal impairment has been reported in association with pyoderma gangrenosum but has notbeen described in PASH syndrome. We believe this to be the first reported case of a patient who developed PASH syndrome in the setting of ESRD.
Description
CITATION: De Wet, J., et al. 2017. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatology Online Journal, 23(12):1-6.
The original publication is available at https://escholarship.org/uc/doj
Keywords
Chronic renal failure, Tumor necrosis factor
Citation
De Wet, J., et al. 2017. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatology Online Journal, 23(12):1-6
URI
http://hdl.handle.net/10019.1/104276
Collections
Research Articles (Dermatology)